MUHAMMAD AKBAR RAMADHAN MUNANDAR; HENDRA PRIATNA MUNANDAR; LIANA HERLINA. Cost-Effectiveness of Pembrolizumab as First-Line Treatment for PD-L1 Positive NSCLC: A Systematic Review. The International Journal of Medical Science and Health Research, [S. l.], v. 23, n. 2, p. 64–130, 2026. DOI: 10.70070/h3zdy035. Disponível em: https://internationalmedicaljournal.org/index.php/ijmhsr/article/view/461.. Acesso em: 21 oct. 2026.